logo-loader

Pharmaxis has the "secret sauce" for developing drugs through to commercialisation

Published: 09:45 22 May 2018 AEST

Pharmaxis Ltd (ASX:PXS) non-executive director Dr Kathleen Metters explains what attracted her to the board of the pharmaceutical research company less than a year ago, following a long and illustrious career in big pharma.

"This is an incredibly innovative research group. They have managed to move into the clinic - and not just into the clinic but into pre-clinical development - compounds for particular, what we call, therapeutic targets to test new mechanisms that has never been done in the industry before," says Metters.

"I realised they just had all the qualities to do it again and again and again. They are really rigorous scientists... they know every step of the business; this is a small company but it goes from research through to commercialisation, so they have really exquisite line of sight on what they need to do to bring forward new therapies," Metters continues.

Pharmaxis is in talks for a partnership deal on its LOXL2 anti‐fibrotic program, with hopes of announcing a partner in the second half of this year.

Syntara to start Phase 2 study targeting MDS

Syntara Ltd (ASX:SNT) CEO Gary Phillips joins Proactive’s Jonathan Jackson to share insights on the company's expansion of its lead drug, SNT-5505, into new medical indications, including a promising Phase 2 study targeting myelodysplastic syndrome (MDS). Phillips highlighted the significance of...

on 14/2/24